Select a medication above to begin.
Idamycin PFS
idarubicin
Black Box Warnings .
Cardiomyopathy
myocardial damage, including acute left ventricular failure can occur during or after tx D/C; risk increased in patients who have received prior anthracyclines or who have pre-existing cardiac disease; assess LVEF before, during, and after tx
Secondary Malignancy
secondary AML and myelodysplastic syndrome occur at a higher incidence
Extravasation
can result in local tissue injury and necrosis; immediately D/C infusion and institute recommended management procedures
Adult Dosing .
Dosage forms: INJ
Special Note
- [uses, dosing may vary]
- Info: refer to institution protocols and pkg insert prior to prescribing for uses and dosing including toxicity-related dose adjustments
AML, induction tx
- [12 mg/m^2/dose IV x1 on days 1-3 of cycle]
- Info: use with cytarabine; may give 2nd cycle if response not achieved with 1st cycle
renal dosing
- [adjust dose amount]
- CrCl <30: decr. usual dose by 33%
- HD: decr. usual dose by 33%; no supplement after dialysis; PD: decr. usual dose by 33%; no supplement
hepatic dosing
- [see below]
- bilirubin 2.6-5: decr. usual dose by 50%; bilirubin >5: avoid use
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.